

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: OC01620K APPLICANT: APPLICATION NO.: 10/654,163

١	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Tim thy J. Guzi tal.						
	(Use several sheets if necessary))	FILING DATE: 09/03/2003			GROUP 1624		
				U.S. PATI	ENT DOCUM	MENTS					
	'EXAMINER DOCUMENT			DATE	NAME		CU	ASS		FILING	
INIT	AL			Dübte	Diplos of of			CLASS	APPRO	PRIATE	
*	<u>-</u> [AA	US 5,571,813	11/05/1996	Rühter et al. Rühter et al.		-	┼	 	 	
-	1	AB	US 5,602,136 US 5,602,137	02/11/1997	Rühter et al.		-	├	 -		
	+-	AC AD	US 5,688,949	11/18/1997	Inoue et al.		┼─	 	 		——
	╁╌	AE	US 5,707,997	01/13/1998	Shoji et al.			-	1		1
-	+	AF	US 5,919,815	07/06/1999	Bradley et al.		1		1		
	+-	AG	US 6,040,321	03/21/2000	Kim et al.		1 1		H		
) 	AH	US 6,191,131	02/20/2001	He et al.		1			<u> </u>	
1	1/	AJ	US 6,262,096	07/17/2001			\Box		1		
			Dumo	nt et al.	П						
		<u>. </u>		FOREIGN PA	ATENT DOC	UMENTS			V		
 	DOCUMENT NUMBER			DATE	COUNTRY		CLASS	SUB-	TRANS	LATION	
i .			NUMBER						CLASS	YES	NO
		AK	EP 0 628 559	04/03/2002	Eur	ope	T		1		
		AL	EP 1 334 973	08/13/2003		оре					
		AM	WO 02/40485	05/23/2002	PCT						
		AN	WO 02/50079	06/27/2002	P	CT					
			CT.								
		OTI	HER DOCUMEN	TS (Including	Author, Title	e, Date, Pert	inen	t Pa	iges, Et	c.)	
0	10	AP	Vesely et al., "Inhibi	tion of Cyclin-D	ependent Kina	ses by Purine A	malo	gues	", Eur. J.	Bloche	m
	5		(1994), 224: 771-78	6				_			
	1	AQ	Kim et al., "Discove	ry of Aminothia	zole Inhibitors	of Cyclin-Deper	ndent	Kina	se 2: Sy	nthesis,	X-ray
	1	Crystallographic Analysis, and Biological Activities", Journal of Medical Chemistry, Page									
	4		EST:22.3, A-W.	Now Co	-iller of CDV/CS	V 2 Johibitors	CAD	Ch.	dy Comb	l Ctruct	hur in
AR Mettey et al., "Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal S							31 AR/2	1. 222-			
Complex with CDK2, Enzyme Selectivity, and Cellular Effects", J. Med. Chem. (2003), 46(2): 236. AS Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-								.j. 222			
	a pyrimidines", J. Med. Chem. (1977), 20(2): 296-299.										
AT Senderowicz et al. "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Depender									ndent		
1 1	Kinase Inhibitor, in Patients with Refractory Neoplasms", Journal of Clinical Oncology (September									tember	
1998), 16(9): 2986-2999.											
AU Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selec											
the Cyclin-Dependent Kinases CDC2, CDK2					C2, CDK2 and	and CDK5", Eur. J. Biochem. (1997), 243:527-536.					
1 · 1		AV	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various								Manuat
Antineoplastic Agents: The Importance of Sequence of Administration", Cancer Research							search (August			
 	15, 1997), 57: 3375-3380. AW Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensis								otensin		
		IA \A/	II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", Chem. Pharm. Bull. (1999), 47(7)							31011381	
		AW	II Recentor Antagor	nists. Pyrazoloľ	1.5-alpyrimiding	Derivatives"	Chen	n. Ph	arm, Bull	(1999)), 47(7): İ
		AW	II Receptor Antagor	nists: Pyrazolo[1,5-α]pyrimidine	e Derivatives",	Chen	n. Ph	arm. Bull	. (1999)), 47(7):
Λ		AW AX	II Receptor Antagor 928-938.	nists: Pyrazolo[arm. Bull	. (1999)	
d			II Receptor Antagor	nists: Pyrazolo[Studies on the	Azaindolizine C n. Pharm. Bull (ompounds. XI. 1962), 10: 620	Synti	nesis	arm. Bull	. (1999)	
EXAM	HINEF	AX	II Receptor Antagor 928-938. Yasuo Makisumi, "S	nists: Pyrazolo[Studies on the	Azaindolizine C n. Pharm. Bull (ompounds. XI.	Synti	nesis	arm. Bull	. (1999)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAR 2 2 2004 H

DUPLICATE

Sheet 1 of 1

	Coordiday	4 4 4 6	110.55	0.4 DT1.451		r						
Re	FOREPTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY, DOCKE OC01620K	APPLICATION NO.: 10/654,163					
	INFORMATION DISCLOSURE STATEMENT					APPLICANT:	1.0,004,	7004,100				
	BY APPLICANT						Timothy J. Guzi et al.					
		(Use several sheets if necessary)					FILING DATE:			GROUP:		
	(Ose several sheets if fiecessal				09/03/2003							
	U.S. PATENT DOCUMENTS											
	*EXAMINER	To unit				ME	CLASS	SUB-	FILING	DATE IF		
	INITIAL	AA	NUMBER	 			 	CLASS	APPRO	PRIATE		
		AB		 	 		 	 				
		AC		 			 	 				
		AD		 	 		 	 				
	·	AE		1	-		 		 			
		AF					 	 				
		AG		 			 		 			
٠		AH			† · · · · · · · · · · · · · · · · · · ·		 					
		Al										
		AJ								-		
		AK			[
				FOREIGN F	PATENT DOC	UMENTS						
ĺ			DOCUMENT	DATE	COUNTRY		CLASS	SUB- TRANSLATION				
			NUMBER					CLASS	YES	NO		
		AL	DE 102 23 917 A1	12/11/2003	Germany							
		AM	EP 1 199 306 A1	04/24/2002	Europe		<u> </u>					
- 1		AN		06/05/1996	Europe							
,	1/	AO	WO 02/50079 A1	06/27/2002	WIPO				•			
٠ ا	<u> </u>	AP	WP 03/091256 A1	11/06/2003	WIPO							
.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	AQ Adrian M. Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase											
	N		Modulators", J. Natl. Cancer Inst., 92(5):376-387 (March 1, 2000)									
	11.	AR	Teruki Honma et al., "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New									
ŀ	00		de Novo Design Strategy and Library Design", J. Med. Chem., 44: 4615-4627 (2001).									
ŀ		AS										
ŀ		AT										
ł		AU AV	<u> </u>									
H	EXAMINER		1/1/	-/	DATE OF	NOIDEDER						
	EXAMINER DATE CONSIDERED											
ł		}	1. 100	19,		6/H	la					
1	*EXAMINE	₹: In	itial if reference consi	dered, whether	er or not citation i	s in conforman	Ce with M	PFP 600	Draw t	ine		
V	through cita	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw tine hrough citation if not in conformance and net considered. Include copy of this form with next communication to										
- 1	applicant.					. •		~		1		